LIO-1: Initial Phase 2 experience with Lucitanib plus Nivolumab in Patients with persistent or recurrent Cervical Cancer (NCT04042116; ENGOT-GYN3/AGO/LIO)F. Heitz, A. Oaknin,F. J. Backes,E. Van Nieuwenhuysen, R. N. Eskander,A. Gonzalez-Martin,V Makker,C. Marth,M. Patel, R. T. Penson,A. Redondo, M. J. R. Perez,E. Hamilton, P. Wimberger,N. Concin,J. Go, K. Wride, D. Lepley, R. Dusek,T. Cameron,S. PignataGEBURTSHILFE UND FRAUENHEILKUNDE（2022）引用 0|浏览9暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
